Expert Interview
Looking at the Longer-Term Follow-Up of Western Patients treated with Summit Therapeutics' ivonescimab (PD-1xVEGF bispecific) plus chemo for EGFR-mutant NSCLC
Ticker(s): SMMTInstitution: Duke
- Professor of Medicine at Duke University and member of Thoracic Oncology at Duke Cancer Institute
- Treats 75 patients with PD-L1- positive Advanced NSCLC
- Research focus is clinical trials on non-small cell lung cancer and small cell lung cancer,
How many patients with NSCLC do you currently manage?
Added By: dami_adminOn a scale of 1-10 (10 being the highest) how excited are you for ivonescimab
Added By: dami_adminHow do you interpret the differences between the most recent ivonescimab data and the findings from studies conducted in non-Western patient populations?
Added By: ben_adminHow do you view the role of a PD-1xVEGF bispecifics in NSCLC?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
